In yesterday’s Wall Street session, X4 Pharmaceuticals Inc. (NASDAQ:XFOR) shares traded at $1.04, up 9.47% from the previous session.
As of this writing, 8 analysts cover X4 Pharmaceuticals Inc. (NASDAQ:XFOR). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $3.00, we find $4.50. Given the previous closing price of $0.95, this indicates a potential upside of 373.68 percent. XFOR stock price is now 4.47% away from the 50-day moving average and -17.24% away from the 200-day moving average. The market capitalization of the company currently stands at $123.28M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
There are 0 analysts who have given it a hold rating, whereas 8 have given it a buy rating. Brokers who have rated the stock have averaged $4.50 as their price target over the next twelve months.
With the price target of $3, Cantor Fitzgerald recently initiated with Overweight rating for X4 Pharmaceuticals Inc. (NASDAQ: XFOR). On December 12, 2022, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $3, while ‘Oppenheimer’ rates the stock as ‘Outperform’.
In other news, Mostafa Adam S., Chief Financial Officer sold 27,721 shares of the company’s stock on Feb 13. The stock was sold for $25,781 at an average price of $0.93. Upon completion of the transaction, the Chief Financial Officer now directly owns 146,196 shares in the company, valued at $0.15 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 13, President and CEO Ragan Paula sold 21,695 shares of the business’s stock. A total of $20,176 was realized by selling the stock at an average price of $0.93. This leaves the insider owning 613,215 shares of the company worth $0.64 million. A total of 0.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in XFOR stock. A new stake in X4 Pharmaceuticals Inc. shares was purchased by CVI HOLDINGS, LLC during the first quarter worth $2,477,000. LYNWOOD CAPITAL MANAGEMENT INC. invested $2,241,000 in shares of XFOR during the first quarter. In the first quarter, GHOST TREE CAPITAL, LLC acquired a new stake in X4 Pharmaceuticals Inc. valued at approximately $1,040,000. CITADEL ADVISORS LLC acquired a new stake in XFOR for approximately $983,000. SCHONFELD STRATEGIC ADVISORS LLC purchased a new stake in XFOR valued at around $931,000 in the second quarter. In total, there are 70 active investors with 35.00% ownership of the company’s stock.
Tuesday morning saw X4 Pharmaceuticals Inc. (NASDAQ: XFOR) opened at $0.9300. During the past 12 months, X4 Pharmaceuticals Inc. has had a low of $0.65 and a high of $2.41. As of last week, the company has a debt-to-equity ratio of 0.54, a current ratio of 3.00, and a quick ratio of 3.00. The fifty day moving average price for XFOR is $0.9956 and a two-hundred day moving average price translates $1.2566 for the stock.
The latest earnings results from X4 Pharmaceuticals Inc. (NASDAQ: XFOR) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.26, beating analysts’ expectations of -$0.3 by 0.04. This compares to -$0.76 EPS in the same period last year. The company reported revenue of $20.15 million for the quarter, compared to $19.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.41 percent.
X4 Pharmaceuticals Inc.(XFOR) Company Profile
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
